Resveratrol and curcumin enhance pancreatic β-cell function by inhibiting phosphodiesterase activity

Journal of Endocrinology

Volumn 223, Issue 2, 2014, Pages 107-117

  Rouse, Michael ^a   Younès, Antoine ^a   Egan, Josephine M ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Curcumin; Phosphodiesterase; Resveratrol; Type 2 diabetes; Cell

Indexed keywords

CURCUMIN; CYCLIC AMP; GLUCOSE; MESSENGER RNA; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; PHOSPHODIESTERASE 3B; PHOSPHODIESTERASE 8A; RESVERATROL; UNCLASSIFIED DRUG; INSULIN; PHOSPHODIESTERASE INHIBITOR; STILBENE DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN RELEASE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; ANIMAL; CELL CULTURE; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY;

ANIMALS; CELLS, CULTURED; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MICE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; STILBENES;

EID: 84915756218     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-14-0335     Document Type: Article

References (54)

1. Abusnina A, Keravis T, Yougbaré I, Bronner C & Lugnier C 2011 Antiproliferative effect of curcumin onmelanoma cells is mediated by PDE1A inhibition that regulates the epigenetic integrator UHRF1. Molecular Nutrition & Food Research 55 1677-1689. (doi:10.1002/mnfr.201100307)
2. Aggarwal BB, Kumar A & Bharti AC 2003 Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Research 23 363-398.
3. Arun N & Nalini N 2002 Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats. Plant Foods for Human Nutrition 57 41-52. (doi:10.1023/A:1013106527829)
4. Balamurugan AN, Akhov L, Selvaraj G & Pugazhenthi S 2009 Induction of antioxidant enzymes by curcumin and its analogues in human islets: implications in transplantation. Pancreas 159 85-93. (doi:10.1097/ MPA.0b013e318196c3e7)
5. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K et al. 2006 Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444 337-342. (doi:10.1038/nature05354)
6. Beaudeux JL, Nivet-Antoine V & Giral P 2010 Resveratrol: a relevant pharmacological approach for the treatment of metabolic syndrome? Current Opinion in Clinical Nutrition and Metabolic Care 13 729-736. (doi:10.1097/MCO.0b013e32833ef291)
7. Bhatt JK, Thomas S & Nanjan MJ 2012 Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutrition Research 32 534-541. (doi:10.1016/j.nutres.2012.06.003)
8. Brasnyó P, Molnár GA, Mohás M, Markó L, Laczy B, Cseh J, Mikolás E, Szijártó IA, Mérei A, Halmai R et al. 2011 Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway intype 2 diabetic patients. British Journal of Nutrition 106 383-389. (doi:10.1017/S0007114511000316)
9. Cantin LD, Magnuson S, Gunn D, Barucci N, Breuhaus M, Bullock WH, Burke J, Claus TH, Daly M, Decarr L et al. 2007 PDE-10A inhibitors as insulin secretagogues. Bioorganic & Medicinal Chemistry Letters 17 2869-2873. (doi:10.1016/j.bmcl.2007.02.061)
10. Carrizzo A, Forte M, Damato A, Trimarco V, Salzano F, Bartolo M, Maciag A, Puca AA & Vecchione C 2013 Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases. Food and Chemical Toxicology 61 215-226. (doi:10.1016/j.fct.2013.07.021)
11. Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C Jirawatnotai S 2012 Curcumin extract for prevention of type 2 diabetes. Diabetes Care 35 2121-2127. (doi:10.2337/dc12-0116)
12. Cote RH 2007 Photoreceptor phosphodiesterase (PDE6): A G-proteinactivated PDE regulating visual excitation in rod and cone photoreceptor cells. In Cyclic Nucleotide Phosphodiesterases in Health and Disease, 1st Edn, Ch 8, pp 165-194. Eds J Beavo, S Francis & M Houslay. Boca Raton, FL: CRC Press.
13. Dov A, Abramovitch E, Warwar N & Nesher R 2008 Diminished phosphodiesterase-8B potentiates biphasic insulin response to glucose. Endocrinology 149 741-748. (doi:10.1210/en.2007-0968)
14. El-Azab MF, Attia FM & El-Mowafy AM 2011 Novel role of curcumin combined with bone marrow transplantation in reversing experimental diabetes: effects on pancreatic islet regeneration oxidative stress, and inflammatory cytokines. European Journal of Pharmacology 658 41-48. (doi:10.1016/j.ejphar.2011.02.010)
15. El-Mowafy AM 2002 Resveratrol activatesmembrane-bound guanylyl cyclase in coronary arterial smooth muscle: a novel signaling mechanism in support of coronary protection. Biochemical and Biophysical Research Communications 291 1218-1224. (doi:10.1006/bbrc.2002.6598)
16. El-Mowafy AM & Alkhalaf M 2003 Resveratrol activates adenylyl-cyclase in human breast cancer cells: a novel, estrogen receptor-independent cytostaticmechanism. Carcinogenesis 24 869-873. (doi:10.1093/carcin/bgg015)
17. Fan X, Zhang C, Liu D, Yan J & Liang H 2013 The clinical applications of curcumin: current state and the future. Current Pharmaceutical Design 19 2011-2031. (doi:10.2174/1381612811319110005)
18. Fiori JL, Shin YK, Kim W, Krzysik-Walker SM, González-Mariscal I, Carlson OD, Sanghvi M, Moaddel R, Farhang K, Gadkaree SK et al. 2013 Resveratrol prevents β-cell dedifferentiation in nonhuman primates given a high-fat/high-sugar diet. Diabetes 62 3500-3513. (doi:10.2337/db13-0266)
19. Gerhart-Hines Z, Dominy JE Jr, Blättler SM, Jedrychowski MP, Banks AS, Lim JH, Chim H, Gygi SP & Puigserver P 2011 The cAMP/PKA pathway rapidly activates SIRT1 to promote fatty acid oxidation independently of changes in NADC. Molecular Cell 44 851-863. (doi:10.1016/j.molcel. 2011.12.005)
20. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U & Shaw JE 2014 Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Research and Clinical Practice 103 137-149. (doi:10.1016/j.diabres.2013.11.002)
21. Härndahl L, Jing XJ, Ivarsson R, Degerman E, Ahrén B, Manganiello VC, Renström E & Holst LS 2002 Important role of phosphodiesterase 3B for the stimulatory action of cAMP on pancreatic β-cell exocytosis and release of insulin. Journal of Biological Chemistry 277 37446-37455. (doi:10.1074/jbc.M205401200)
22. Härndahl L, Jing XJ, Ivarsson R, Degerman E, Ahrén B, Manganiello VC, Renström E & Holst LS 2004 β-Cell-targeted overexpression of phosphodiesterase 3B in mice causes impaired insulin secretion, glucose intolerance, and deranged islet morphology. Journal of Biological Chemistry 279 15214-15222. (doi:10.1074/jbc.M308952200)
23. Holt PR, Katz S & Kirshoff R 2005 Curcumin therapy in inflammatory bowel disease: a pilot study. Digestive Diseases and Sciences 50 2191-2193. (doi:10.1007/s10620-005-3032-8)
24. Hussain HE 2002 Hypoglycemic, hypolipidemic, and antioxidant properties of combination of curcumin from Curcuma longa, Linn, and partially purified product from Abroma augusta, Linn. in streptozotocin induced diabetes. Indian Journal of Clinical Biochemistry 17 33-43. (doi:10.1007/BF02867969)
25. Kahn SE 2003 The relative contribution of insulin resistance and b cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46 3-19. (doi:10.1007/s00125-003-1190-9)
26. Kar P, Laight D, Rooprai HK, Shaw KM & Cummings M 2009 Effects of grape seed extract in type 2 diabetic subjects at high cardiovascular risk: a double blind randomized placebo controlled trial examining metabolic markers, vascular tone, inflammation, oxidative stress and insulin sensitivity. Diabetic Medicine 26 526-531. (doi:10.1111/ j.1464-5491.2009.02727.x)
27. Kumar BJ & Joghee NM 2013 Resveratrol supplementation in patients with type 2 diabetes mellitus: a prospective, open label, randomized controlled trial. International Research Journal of Pharmacy 4 245-249. (doi:10.7897/2230-8407.04849)
28. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P et al. 2006 Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1a. Cell 127 1109-1122. (doi:10.1016/j.cell.2006.11.013)
29. Lao CD, Ruffin MT IV, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL & Brenner DE 2006 Dose escalation of a curcuminoid formulation. BMC Complementary and Alternative Medicine 6 10. (doi:10.1186/1472-6882-6-10)
30. Marchal J, Blanc S, Epelbaum J, Aujard F & Pifferi F 2012 Effects of chronic calorie restriction or dietary resveratrol supplementation on insulin sensitivity markers in a primate, Microcebus murinus. PLoS ONE 7 e34289. (doi:10.1371/journal.pone.0034289)
31. Marshak S, Leibowitz G, Bertuzzi F, Socci C, Kaiser N, Gross DJ, Cerasi E & Melloul D 1999 Impaired β-cell functions induced by chronic exposure of cultured human pancreatic islets to high glucose. Diabetes 48 1230-1236. (doi:10.2337/diabetes.48.6.1230)
32. Mehats C, Andersen CB, Filopanti M, Jin SL & Conti M 2002 Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends in Endocrinology and Metabolism 13 29-35. (doi:10.1016/S1043-2760(01)00523-9)
33. Meng B, Li J & Cao H 2013 Antioxidant and antiinflammatory activities of curcumin on diabetes mellitus and its complications. Current Pharmaceutical Design 19 2101-2113. (doi:10.2174/1381612811319110011)
34. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS & Marks JS 2003 Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. Journal of the American Medical Association 289 76-79. (doi:10.1001/jama.289.1.76)
35. Movahed A, Nabipour I, Lieben Louis X, Thandapilly SJ, Yu L, Kalantarhormozi M, Rekabpour SJ & Netticadan T 2013 Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evidence-Based Complementary and Alternative Medicine 2013 851267. (doi:10.1155/2013/851267)
36. Nawrocki AR, Rodriguez CG, Toolan DM, Price O, Henry M, Forrest G, Szeto D, Keohane CA, Pan Y, Smith KM et al. 2014 Genetic deletion and pharmacological inhibition of phosphodiesterase 10A protects mice from diet-induced obesity and insulin resistance. Diabetes 63 300-311. (doi:10.2337/db13-0247)
37. Pari L & Murugan P 2005 Effect of tetrahydrocurcumin on blood glucose, plasma insulin and hepatic key enzymes in streptozotocin induced diabetic rats. Journal of Basic and Clinical Physiology and Pharmacology 16 257-274. (doi:10.1515/JBCPP.2005.16.4.257)
38. Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, Ke H, Rehmann H, Taussig R, Brown AL et al. 2012 Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148 421-433. (doi:10.1016/j.cell.2012.01.017)
39. Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stødkilde-Jørgensen H, Møller N, Jessen N, Pedersen SB & Jørgensen JO 2013 High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 62 1186-1195. (doi:10.2337/db12-0975)
40. Rotella DP 2002 Phosphodiesterase 5 inhibitors: current status and potential applications. Nature Reviews. Drug Discovery 1 674-682. (doi:10.1038/nrd893)
41. Samson SL & Garber AJ 2014 Metabolic syndrome. Endocrinology andMetabolism Clinics of North America 43 1-23. (doi:10.1016/j.ecl.2013.09.009)
42. ShaoW,Yu Z,Chiang Y, Yang Y, Chai T, Foltz W, Lu H, Fantus IG & Jin T 2012 Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PLoS ONE 7 e28784. (doi:10.1371/journal.pone.0028784)
43. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R & Srinivas PS 1998 Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica 64 353-356. (doi:10.1055/ s-2006-957450)
44. Soderling SH & Beavo JA 2000 Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Current Opinion in Cell Biology 12 174-179. (doi:10.1016/S0955-0674(99)00073-3)
45. Soldevila G, Buscema M, Marini V, Mirakian R, Deuss V, Sutton R, James R, Lake S, Robertson P, Pujol-Borrell R et al. 1991 Transfection with SV40 genes of human pancreatic endocrine cells. Journal of Autoimmunity 4 381-396. (doi:10.1016/0896-8411(91)90154-5)
46. Soufi FG, Sheervalilou R, VardianiM, Khalili M, Alipour MR 2012 Chronic resveratrol administration has beneficial effects in experimental model of type 2 diabetic rats. Endocrine Regulations 46 83-90. (doi:10.4149/ endo_2012_02_83)
47. Su HC, Hung LM & Chen JK 2006 Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. American Journal of Physiology. Endocrinology and Metabolism 290 1339-1346. (doi:10.1152/ajpendo.00487.2005)
48. Szkudelski T & Szkudelska K 2011 Anti-diabetic effects of resveratrol. Annals of the New York Academy of Sciences 1215 34-39. (doi:10.1111/j. 1749-6632.2010.05844.x)
49. Trimmers S, Hesselink MK & Schrauwen P 2013 Therapeutic potential of resveratrol in obesity and type 2 diabetes: new avenues for health benefits? Annals of the New York Academy of Sciences 1290 83-89. (doi:10.1111/nyas.12185)
50. Waddleton D, Wu W, Feng Y, Thompson C, Wu M, Zhou YP, Howard A, Thornberry N, Li J & Mancini JA 2008 Phosphodiesterase 3 and 4 comprise the major cAMP metabolizing enzymes responsible for insulin secretion in INS-1 (832/13) cells and rat islets. Biochemical Pharmacology 76 884-893. (doi:10.1016/j.bcp.2008.07.025)
51. Walz HA, Härndahl L, Wierup N, Zmuda-Trzebiatowska E, Svennelid F, Manganiello VC, Ploug T, Sundler F,Degerman E, AhrénBet al. 2006 Early and rapid development of insulin resistance, islet dysfunction and glucose intolerance after high-fat feeding inmice overexpressing phosphodiesterases 3B. Journal of Endocrinology 189 629-641. (doi:10.1677/joe.1.06522)
52. Walz HA, Wierup N, Vikman J, Manganiello VC, Degerman E, Eliasson L & Holst LS 2007 β-Cell PDE3B regulates Ca2C-stimulated exocytosis of insulin. Cellular Signalling 19 1505-1513. (doi:10.1016/j.cellsig.2007.01.030)
53. Yoshino J, Conte C, Fontana L, Mittendorfer B, Imai S, Schechtman KB, Gu C, Kunz I, Rossi Fanelli F, Patterson BW et al. 2012 Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metabolism 16 658-664. (doi:10.1016/j.cmet.2012.09.015)
54. Younès A, Lukyanenko YO, Lyashkov AE, Lakatta EG & Sollott SJ 2011 A bioluminescence method for direct measurement of phosphodiesterase activity. Analytical Biochemistry 417 36-40. (doi:10.1016/ j.ab.2011.05.036)